Christopher Mutz - 12 Feb 2026 Form 4 Insider Report for ANI PHARMACEUTICALS INC (ANIP)

Reporting relationship: HEAD OF RARE DISEASE
Issuer ticker: ANIP
Reported as of: 12 Feb 2026
Net transaction value: -$967,565
SEC form: 4
Accepted by SEC: 17 Feb 2026, 16:08:03 UTC
Prior SEC filing: 13 Feb 2026
Next SEC filing: 23 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Christopher Mutz, by attorney-in-fact Meredith W. Cook

Key filing fact

Christopher Mutz filed Form 4 for ANI PHARMACEUTICALS INC (ANIP) on 17 Feb 2026.

Key facts

This page summarizes Christopher Mutz's Form 4 filing for ANI PHARMACEUTICALS INC (ANIP).
3 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 17 Feb 2026, 16:08.

Change

Previous filing in this sequence was filed on 13 Feb 2026.
Current net transaction value: -$967,565.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001846487 Primary reporting owner

Mutz Christopher

Relationship: HEAD OF RARE DISEASE
Address: C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE
Signature: /s/ Christopher Mutz, by attorney-in-fact Meredith W. Cook
Signature date: 17 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ANIP transaction

Common Stock

Tax liability

Transaction value: $243,369
Shares: -3,173
Change %: -3.1%
Price: $76.70
Shares after: 99,598
Date: 12 Feb 2026
Ownership: Direct
Footnotes: F1

ANIP transaction

Common Stock

Sale

Transaction value: $538,300
Shares: -7,032
Change %: -7.1%
Price: $76.55
Shares after: 92,566
Date: 12 Feb 2026
Ownership: Direct
Footnotes: F2, F3

ANIP transaction

Common Stock

Tax liability

Transaction value: $185,896
Shares: -2,403
Change %: -2.6%
Price: $77.36
Shares after: 90,163
Date: 14 Feb 2026
Ownership: Direct
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,202 shares of restricted stock, the grant of which was previously reported on February 18, 2025.

Footnote F2

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

Footnote F3

The shares were sold in multiple trades at prices ranging from $75.43 to $76.92. The price reported above reflects the weighted average sales price.

Footnote F4

Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,697 shares of restricted stock, the grant of which was previously reported on February 16, 2024.